MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

The historical lack of preclinical models reflecting the genetic heterogeneity of multiple
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …

Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple
myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of …

Entry of antigen-specific T cells into human tumors is critical for immunotherapy, but the
underlying mechanisms are poorly understood. Here, we combined high-dimensional …

Multiple myeloma is the second most common hematological malignancy. Despite
significant advances in treatment, relapse is common and carries a poor prognosis. Thus, it …

Multiple myeloma (MM) is consistently preceded by precursor conditions recognized
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …

Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM).
We report the results of a study of 82 patients with both targeted sequencing that included a …

The landscape of structural variants (SV) in multiple myeloma remains poorly understood.
Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with …